European Urology published a clinical update in Research Highlights on 02 Feb 2026.
The item focuses on Updated 5-year Survival Results from PURE-01, a Phase 2 Study of Neoadjuvant Pembrolizumab Followed by Radical Cystectomy in Patients with Muscle-invasive Bladder Cancer.
Review the original article for the full source wording and details.